16192 Coastal HWY

Lewes, DE 19958

Phone Number

(844) 883-5723

Office Hours

Mon - Fri 9am - 5pm

iDose TR Billing in 2026: Medicare LCD Status and What to Document Now

67028 CPT Code: Intravitreal Injection Billing and 2026 Reimbursement
Created by: The Billing Service Quotes Editorial Team.
Technical Review: Tim Daniels, Director of Strategic Accounts, Billing Service Quotes

Is iDose TR still covered by Medicare in November 2026?

As of November 2026, iDose TR billing refers to reporting CPT 0660T for the implantation and HCPCS J7355 at 75 units for the travoprost implant, and Medicare coverage still runs under existing MAC policy. The multi-MAC proposed LCD posted May 21, 2026 has not been finalized, Glaukos confirmed on October 28, 2026 that there is no update, and any final LCD would take effect 45 days after publication.

No final LCD yet: The MACs behind the proposal have until about May 2027 to finalize or abandon it, so coverage could change with 45 days of notice.

Proposed criteria are strict: The draft requires documented failure of at least two topical drops and failure of SLT before Medicare would cover the implant.

Diagnosis must match the label: Ocular hypertension (H40.05-) and open-angle glaucoma (H40.1-) codes support the claim, while a glaucoma suspect code such as H40.013 is not on AAOE’s iDose code list.

What Changed With iDose TR Coverage

On May 21, 2026, five Medicare Administrative Contractors posted matching proposed Local Coverage Determinations for the anterior segment intraocular nonbiodegradable drug-eluting system category. That category covers one product, the Glaukos iDose TR travoprost implant. According to the CMS Medicare Coverage Database, the multi-MAC effort involved CGS Administrators, Noridian, National Government Services (now Wellpoint Federal), Palmetto GBA, and Wisconsin Physicians Service. The comment period on Palmetto GBA’s proposed LCD DL40367 closed July 4, 2026.

The newest development came on October 28, 2026, during the Glaukos third quarter earnings call. Leadership said there were no new LCD updates, that the MACs must act on or abandon the drafts within one year of the May posting, and that any final LCD would carry a 45-day waiting period. On the same October 28 call, Glaukos reported about $76 million in quarterly iDose TR sales, with growth from the National Government Services fee-for-service population, Medicare Advantage, and commercially insured patients.

That combination makes this a billing story now. Volume is rising, the coverage rules are unsettled, and the timing of a final decision has not been announced. A final LCD could post in December and take effect in late January, or not arrive until spring.

Other payers are not waiting. Humana’s Virginia Medicaid policy for intraocular drug-eluting implants, policy HUM-VA-2672-000, took effect October 28, 2026 and requires two failed or poorly tolerated ophthalmic medications before it covers 0660T or 0661T. It does not require SLT, unlike the Medicare draft. Practices now face at least two different step-therapy standards for the same implant, depending on who pays the claim.

Does the proposed iDose LCD apply to my practice?

The proposed LCD applies only to Medicare Part B claims processed by CGS, Noridian, National Government Services, Palmetto GBA, or Wisconsin Physicians Service. Practices billing Novitas Solutions or First Coast Service Options were not part of the proposal. Medicare Advantage, Medicaid, and commercial plans follow their own policies, although many borrow Medicare criteria when they update.

Confirm jurisdiction first, because the same patient can be covered in one state and challenged in another. Palmetto’s version of the draft lists Alabama, Georgia, Tennessee, South Carolina, Virginia, West Virginia, and North Carolina. Virginia shows how layered this gets: Medicare claims run through Palmetto, while Humana’s Virginia Medicaid plan already enforces its own two-medication rule. Practices in the state can review Virginia medical billing coverage options or our ophthalmology billing support in Virginia Beach.

Site of service does not change the analysis. The LCD governs medical necessity, so ASC, hospital outpatient, and office claims would all depend on the same chart documentation.

One question we hear constantly from practice managers is whether a proposed LCD can be enforced before it is final. It cannot. Until a MAC publishes a final LCD and the 45-day notice period runs, claims are judged under current policy. CGS describes its current approach to Category III iDose TR claims as case-by-case medical necessity review, with use expected to align with the FDA indication.

Why the MACs Proposed Step Therapy

The proposed LCD does not question whether iDose TR lowers intraocular pressure. It rates the evidence as moderate certainty that the implant reduces IOP versus placebo for up to 36 months. The problem, in the MACs’ view, is sequencing. The draft states that the implant is not a first-line therapy, because topical medications and selective laser trabeculoplasty both carry high-quality evidence and society support as initial treatment.

Two data points drive that reasoning. The draft cites the LiGHT trial, which found SLT clinically effective and cost-effective as a primary treatment for open-angle glaucoma over up to six years. It also notes that implantation requires a corneal incision and that no studies compare iDose TR against a combined drops-and-SLT standard of care.

The draft also reflects a multi-MAC Contractor Advisory Committee meeting held November 12, 2025, where subject matter experts agreed that open-angle glaucoma care starts with drops and SLT. The same experts rated the evidence for combining iDose TR with other MIGS procedures as low to nonexistent, which is why the draft bars same-session combinations except phacoemulsification cataract surgery.

The signal for billing teams is broader than one implant. Payers are treating procedural pharmaceuticals like specialty drugs, with step therapy, re-treatment intervals, and chart-level proof of prior failure. Glaukos said it is studying iDose TR with iStent infinite to support a reconsideration request if combination use is restricted. Whether the final version softens the dual drop-and-SLT requirement has not been announced.

What would a final iDose LCD cost an ophthalmology practice?

A final LCD would not lower the payment rate for iDose TR. It would shrink the number of Medicare patients who qualify. Every case without documented drop failure and SLT failure would become a non-covered service, which puts the professional fee, the facility fee, and the drug payment at risk at the same time.

The professional fee is only part of the exposure. According to the AAOE iDose TR coding fact sheet, 2026 Medicare facility payment for 0660T is $4,222.95 in the hospital outpatient setting and $2,203.87 in an ASC. As a Category III code with no RVUs, 0660T is priced by each MAC for the professional fee. AAOE cites a Novitas example of $664.12 for the Dallas locality.

Consider an illustrative scenario. A surgeon places 10 iDose TR implants a month for traditional Medicare patients at an ASC, and four have never had SLT. If a final LCD matched the draft, those four cases would fail coverage. Using the AAOE figures, that is about $2,656 in professional fees and $8,815 in ASC facility payments, or roughly $11,470 a month before the separately paid J7355 drug. Over a year, the exposure approaches $137,700 for one surgeon.

RequirementNo final LCD (current)Proposed LCD DL40367Humana VA Medicaid (Oct 28, 2026)
Failed topical dropsCase-by-case medical necessityAt least 2 drops failed or not toleratedTrial of 2 medications failed or not tolerated
Failed SLTNot specified by an LCDRequiredNot required
With cataract surgeryFollows MAC guidanceAllowed only if all criteria are metNot addressed
With other MIGS, same sessionFollows MAC guidanceNot coveredNot addressed
Re-administrationPer FDA labelNot within 2 yearsNot within 1 year

What should practices do before a final LCD is published?

The goal is to make every iDose TR chart defensible under the strictest version of the rule, so a final LCD changes nothing about how your claims look. These steps work regardless of how the final language lands.

  • Confirm which MAC processes every Medicare Part B claim you bill, including claims from satellite offices and ASCs in neighboring states.
  • Pull every iDose TR case scheduled after mid-December and flag patients whose charts do not show both drop failure and SLT failure.
  • Document each topical medication by name, start and stop dates, IOP response against baseline, and any adverse reaction that forced discontinuation.
  • Record the SLT date, post-laser IOP, and progression evidence such as visual field testing (CPT 92083) so the failure is measurable, not narrative.
  • Code the diagnosis to the highest specificity with laterality and stage, using H40.05- or H40.1- families rather than glaucoma suspect codes.
  • Separate procedures carefully, because the draft bars same-session MIGS combinations other than phacoemulsification cataract surgery.
  • Build an ABN workflow, since AAOE recommends an Advance Beneficiary Notice with modifier GA on 0660T or 0661T for Medicare Part B patients.
  • Verify prior authorization for Medicare Advantage, Medicaid, and commercial plans at scheduling, because AAOE notes they may require it for 0660T, J7355, or both.

In our experience matching providers with billing partners, the practices that ride out coverage changes are the ones whose billing team builds the payer rule into scheduling, not into the appeal. If your team is tracking the iDose LCD on its own, we can connect you with a glaucoma-experienced billing company in our network, typically in touch within two hours of practice verification.

Common iDose Billing Mistakes

The most common issue we see providers run into with iDose TR is not the coverage policy. It is the claim itself. Category III codes draw more manual review, so small errors become denials.

  • Wrong J7355 units: Each implant is 75 micrograms, and the Glaukos billing and coding guide confirms it bills as 75 units, not 1.
  • NDC format errors: AAOE lists the 11-digit NDC as 25357-0100-01, reported with the N4 qualifier in item 24a or loop 2410.
  • Missing JZ modifier: AAOE lists JZ on J7355 to show that no drug was discarded.
  • Billing the drug on specialty pharmacy cases: When the pharmacy supplies the implant, the physician is not paid for J7355, though some payers want a zero-dollar line.
  • Same-day exam codes: AAOE’s NCCI table bundles office E/M codes into 0660T on the same eye, same day, and same session.
  • Missed ADR deadlines: Medicare can request documentation for Category III claims, and a missed response turns a payable claim into a denial.

Providers often come to us after a run of iDose denials traced back to one setup error repeated on every claim. A unit field defaulting to 1 or a 10-digit NDC can reject dozens of cases before anyone sees the pattern. A team that knows Category III ophthalmic claims catches it before the first claim goes out.

In-House Billing vs. Specialized Partner

iDose TR is hard for a general billing team. The procedure code has no national RVUs, professional payment varies by MAC, the drug follows buy-and-bill or specialty pharmacy rules, and coverage may soon depend on step-therapy history that lives in clinical notes. Add Medicaid and Medicare Advantage policies that already differ from the Medicare draft, and the margin for error shrinks.

A specialized ophthalmology billing partner handles those layers as routine work. That means checking the payer and jurisdiction at scheduling, confirming that the chart shows drop and SLT history before surgery, applying the correct units, NDC, and modifiers, and answering ADRs on time. It also means watching for a final LCD so the 45-day notice period goes to preparation, not cleanup.

Ophthalmology Bill Co works with more than 30 ophthalmology billing companies serving practices, including glaucoma and cataract subspecialists, in all 50 states. Billing partners in our network hold certifications from AHIMA, AAPC, MGMA, the AOA, and the AAO, and maintain an average Google rating above 4.7. Practices matched through our network often see denial rates fall 5 to 7 percent within the first 90 days. Learn more about how we match practices with billing partners. To talk through your payer mix first, Tim Daniels, Director of Strategic Accounts at Billing Service Quotes, speaks with practices directly about which partners fit their subspecialty and jurisdiction.

Frequently Asked Questions

What CPT code is used for iDose TR implantation?

Implantation is reported with Category III code 0660T, and removal with reimplantation uses 0661T. The implant itself is billed separately with HCPCS J7355 at 75 units. AAOE’s iDose fact sheet lists a January 2027 sunset date for these Category III codes, so confirm their status in the 2027 CPT code set before January 1.

Is the Medicare iDose LCD final?

No. As of November 2026, the proposed LCD posted May 21, 2026 remains a draft, and Glaukos reported no updates on October 28. The MACs have one year from the May posting to finalize or abandon it, and a final LCD would take effect 45 days after publication.

Can iDose TR be billed with cataract surgery?

Under the proposed LCD, yes, but only if the patient meets every coverage criterion, including failed drops and failed SLT. No other eye surgery or MIGS procedure can be performed in the same session. Until a final LCD is published, same-session billing follows current MAC guidance and payer policy.

Does the proposed LCD require SLT before iDose TR?

Yes. The draft requires a history of failed SLT in addition to failed medical management with at least two topical drops. Failure means the laser did not produce a clinically significant IOP reduction. The draft has no exception for patients who never had SLT, so document that history.

How many units of J7355 should be billed?

Bill 75 units of J7355, because the code describes 1 microgram and each iDose TR implant contains 75 micrograms. Include the 11-digit NDC 25357-0100-01 with the N4 qualifier and append the JZ modifier. If the implant came through a specialty pharmacy, the physician does not bill the drug for payment.

Do Medicare Advantage plans follow the proposed iDose LCD?

Not automatically. Medicare Advantage, Medicaid, and commercial plans set their own coverage policies and may require prior authorization for 0660T, J7355, or both. Some already use step therapy. Humana’s Virginia Medicaid policy, effective October 28, 2026, requires two failed medications but not SLT. Verify each plan at scheduling.

Next Steps

Review how visual field testing with CPT 92083 supports the progression documentation iDose TR coverage depends on.

Virginia practices can compare Virginia medical billing coverage options while Palmetto’s draft is pending.

See our matching process and what makes our billing partner network different.

Get matched with an ophthalmology billing company that tracks LCD changes before they reach your claims. Rates start as low as 2.95%, and matching is free for providers.

Tags :
Weekly News
Share This :

Get Matched In 30 Minutes

Get a FREE Quote

Tell us about your practice and we'll connect you with trusted billing companies.

100% Free to providers — No hidden fees at any stage

Where should we send your quote(s)?

We'll send it directly to your inbox

How many providers does your practice have?

We'll find a billing company that can support your needs

Where is your practice located?

We'll find a billing company that serves providers in your area

loading
Tim Daniels
Online now
Tim Daniels

How can I help?

Send me your number and I'll personally call you in less than 24 hours to discuss any questions you may have about our ophthalmology billing partners

Mon–Fri, 9:00am–5:30pm Or email instead →
Got it — talk soon.
I'll call you within one business hour. Check your phone for an unknown number.